Explore articles, research, and perspectives from the International Perfusion Association.
An expert commentary explains the 2026 AATS approach to HIT testing, anticoagulation, and extracorporeal support after cardiac surgery.
A 76-neonate randomized trial compared initial heparin doses during CPB. Higher initial dosing improved ACT response and a thrombin-generation marker, but clinical benefit and
A matched observational study compares heparin plus antithrombin with bivalirudin in adult ECMO, highlighting associations and important limitations.
A 100-patient randomized CABG trial reported lower bleeding and transfusion exposure with ACT-guided heparin and protamine dosing. Small size, no prospective registration and dosing-table
A four-center randomized trial compared activated clotting time targets of at least 400 and 480 seconds in 1,021 adults undergoing first-time cardiac surgery with
This systematic review and meta-analysis evaluated whether hyperoncotic 20%–25% human albumin affects acute kidney injury after adult on-pump cardiac surgery. Across four studies including
This systematic review examines anticoagulation monitoring during cardiopulmonary bypass in patients with antiphospholipid syndrome, a high-risk prothrombotic condition that can make activated clotting time
This scoping review maps the evidence on ECMO anticoagulation strategies beyond unfractionated heparin. Across 135 included records, direct thrombin inhibitors—especially bivalirudin—were the most studied
This meta-analysis of 12 studies (908 patients) compares 6% hydroxyethyl starch (HES 130/0.4) and 5% albumin in cardiac surgery with cardiopulmonary bypass. Results show
A Europe-wide survey of 114 cardiac surgery centers across 29 countries evaluated current anticoagulation practices during cardiopulmonary bypass. Most centers reported standardized heparin protocols
This retrospective study evaluated the role of fibrinogen replacement therapy (FRT) using fibrinogen concentrate during emergency surgery for acute type A aortic dissection (ATAAD).
This systematic review and meta-analysis of 11 studies (958 ECMO patients) compared reduced-intensity or no heparin anticoagulation with standard heparin strategies. Low/no heparin significantly
